Drug Patents owned by Alkermes Inc

1. List of Aristada drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10112903 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Jun, 2030

(7 years from now)

US8431576 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Oct, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796276 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Jun, 2030

(7 years from now)

US10226458 ALKERMES INC Pharmaceutical compositions comprising sorbitan esters
Mar, 2032

(9 years from now)

US9034867 ALKERMES INC Pharmaceutical compositions comprising sorbitan esters
Nov, 2032

(9 years from now)

US9193685 ALKERMES INC Pharmaceutical compositions having improved storage stability
Oct, 2033

(10 years from now)

US11097006 ALKERMES INC Pharmaceutical compositions having improved storage stability
Oct, 2033

(10 years from now)

US9452131 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(12 years from now)

US10238651 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(12 years from now)

US10813928 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(12 years from now)

US9526726 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(12 years from now)

US11406632 ALKERMES INC Aripiprazole formulations having increased injection speeds
Mar, 2035

(12 years from now)

US11273158 ALKERMES INC Aripiprazole dosing strategy
Apr, 2039

(16 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Market Authorisation Date: 05 October, 2015

Treatment: Treatment of schizophrenia; Treatment of schizophrenia by rapid and continuous intramuscular injection; Treatment of schizophrenia by rapid and continuous injection

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

2. List of Aristada Initio Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10112903 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Jun, 2030

(7 years from now)

US8431576 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Oct, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796276 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Jun, 2030

(7 years from now)

US11154552 ALKERMES INC Aripiprazole prodrug composition
Aug, 2035

(12 years from now)

US10688091 ALKERMES INC Aripiprazole prodrug composition
Aug, 2035

(12 years from now)

US10849894 ALKERMES INC Aripiprazole prodrug composition
Aug, 2035

(12 years from now)

US10016415 ALKERMES INC Aripiprazole prodrug compositions
Sep, 2035

(12 years from now)

US11273158 ALKERMES INC Aripiprazole dosing strategy
Apr, 2039

(16 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Market Authorisation Date: 29 June, 2018

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

3. List of Lybalvi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7262298 ALKERMES INC 4-hydroxybenzomorphans
Nov, 2025

(2 years from now)

US9119848 ALKERMES INC Morphinan derivatives for the treatment of drug overdose
Aug, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11185541 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(8 years from now)

US9126977 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(8 years from now)

US9517235 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(8 years from now)

US10716785 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(8 years from now)

US11351166 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(8 years from now)

US10300054 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(8 years from now)

US11241425 ALKERMES INC Composition for treating mental illness
Aug, 2031

(8 years from now)

US8778960 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Feb, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 28, 2026

Drugs and Companies using OLANZAPINE; SAMIDORPHAN L-MALATE ingredient

NCE-1 date: May, 2025

Market Authorisation Date: 28 May, 2021

Treatment: Method of treating schizophrenia by administering the atypical antipsychotic olanzapine and samidorphan; Method of treating schizophrenia by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain; Method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain; Method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan, with reduction of the adverse metabolic profile; Method of treating schizophrenia by administering the atypical antipsychotic olanzapine and samidorphan, with reduction of the adverse metabolic profile; Method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic